partners

acCELLerate distributes a growing list of recombinant target expressing cell lines provided by assay works. The cell lines cover a broad range of pharmaceutically relevant transmembrane proteins (GPCR's ion channels transporter) generically used for small molecule compound screening lead identification and selectivity testing. The cells are provided in assay ready format at 10 million cells/vial and can be used instantly after thawing. Recovery buffer and assay medium are provided with the cells.

CLS is a privately held cell depository which hosts more than 400 human and animal cell lines - common and unique ones. Many of the cell line can be made available through acCELLerate in assay ready format.  

Recombinant cell lines expressing human ion channels for cardiac safety testing and other applications have been licensed from B'SYS Switzerland for the preparation of patch ready cells. These cells are ready to use after thawing for automated and manual patch clamp set-ups and do no need to be cultivated before. PRCs are provided in single-use allquots of cryopreserved cells at 5 million cells/vial and come with suitable amounts of recovery and patch buffer.

Kidney epithelial cells from the proximal part of the tubulus are and essential tool to specifically asses nephrotoxicity in vitro. ciPTEC cells are conditionally immortalized proximal tubular epithelial cells developed by the Radbound University Nijmegen (NL). The activity of two kidney specific organic anion transporters (OAT1 and OAT3) have been reconstituted in the cells by recombinant expression. acCELLerate provides ciPTEC assay ready cells which have been differentiated before cryopreservation. The cells are ready to use in nephrotoxicity testing without prior cultivation or further differentiation. They are provided in single-use alliquots of 5 million cells/vial and come with suitable amounts of recovery buffer and assay medium.

Founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS), Nanion Technologies is a world leading provider of electrophysiology systems. Nanion’s diverse technologies with throughput capabilities ranging from a single cell up to fully automated high throughput screening recording from 384 cells simultaneously, are used for scientific research, drug discovery and safety testing and are applied by global academic research groups and pharmaceutical companies. In the past decade, Nanion expanded its product range to in vitro systems for membrane pump/transporter, and bilayer recordings, and confluency and contractility measurements from cells monolayers (impedance/EFP). Nanion has subsidiaries in the US, Japan, China and Denmark and distribution partners in multiple countries. Nanion's products are featured regularly in high ranking journals such as Nature, Nature Protocols, and Science.